Willingness to vaccinate against COVID-19 among Bangladeshi adults: Understanding the strategies to optimize vaccination coverage.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

COVID-19/*prevention & control ; COVID-19 Vaccines/*administration & dosage ; Vaccination/*psychology; Adolescent ; Adult ; COVID-19/pathology ; COVID-19/virology ; Cross-Sectional Studies ; Female ; Humans ; Male ; Middle Aged ; Multivariate Analysis ; SARS-CoV-2/isolation & purification ; Social Class ; Socioeconomic Factors ; Surveys and Questionnaires ; Vaccination/economics ; Vaccination/statistics & numerical data ; Vaccination Refusal/statistics & numerical data ; Young Adult

Background: Although the approved COVID-19 vaccine has been shown to be safe and effective, mass vaccination in Bangladeshi people remains a challenge. As a vaccination effort, the study provided an empirical evidence on willingness to vaccinate by sociodemographic, clinical and regional differences in Bangladeshi adults.
Methods: This cross-sectional analysis from a household survey of 3646 adults aged 18 years or older was conducted in 8 districts of Bangladesh, from December 12, 2020, to January 7, 2021. Multinomial regression examined the impact of socio-demographic, clinical and healthcare-releated factors on hesitancy and reluctance of vaccination for COVID-19.
Results: Of the 3646 respondents (2212 men [60.7%]; mean [sd] age, 37.4 [13.9] years), 74.6% reported their willingness to vaccinate against COVID-19 when a safe and effective vaccine is available without a fee, while 8.5% were reluctant to vaccinate. With a minimum fee, 46.5% of the respondents showed intent to vaccinate. Among the respondents, 16.8% reported adequate adherence to health safety regulations, and 35.5% reported high confidence in the country's healthcare system. The COVID-19 vaccine refusal was significantly high in elderly, rural, semi-urban, and slum communities, farmers, day-laborers, homemakers, low-educated group, and those who had low confidence in the country's healthcare system. Also, the prevalence of vaccine hesitancy was high in the elderly population, low-educated group, day-laborers, people with chronic diseases, and people with low confidence in the country's healthcare system.
Conclusion: A high prevalence of vaccine refusal and hesitancy was observed in rural people and slum dwellers in Bangladesh. The rural community and slum dwellers had a low literacy level, low adherence to health safety regulations and low confidence in healthcare system. The ongoing app-based registration for vaccination increased hesitancy and reluctancy in low-educated group. For rural, semi-urban, and slum people, outreach centers for vaccination can be established to ensure the vaccine's nearby availability and limit associated travel costs. In rural areas, community health workers, valued community-leaders, and non-governmental organizations can be utilized to motivate and educate people for vaccination against COVID-19. Further, emphasis should be given to the elderly and diseased people with tailored health messages and assurance from healthcare professionals. The media may play a responsible role with the vaccine education program and eliminate the social stigma about the vaccination. Finally, vaccination should be continued without a fee and thus Bangladesh's COVID vaccination program can become a model for other low and middle-income countries.
Competing Interests: The authors have declared that no competing interests exist.

Environ Health Prev Med. 2017 Mar 14;22(1):1. (PMID: 29165111)
PLoS One. 2020 Oct 9;15(10):e0239254. (PMID: 33035219)
Vaccine. 2020 Dec 3;38(51):8090-8098. (PMID: 33187765)
BMC Public Health. 2017 Feb 16;17(1):203. (PMID: 28209185)
EClinicalMedicine. 2020 Sep;26:100495. (PMID: 32838242)
BMC Public Health. 2015 Jul 07;15:618. (PMID: 26148480)
Vaccine. 2020 Nov 10;38(48):7587. (PMID: 33121656)
Vaccines (Basel). 2021 Feb 16;9(2):. (PMID: 33669441)
J Multidiscip Healthc. 2020 Nov 20;13:1657-1663. (PMID: 33262600)
Front Public Health. 2020 Apr 30;8:154. (PMID: 32426318)
MEDICC Rev. 2019 Jan;21(1):3. (PMID: 31242144)
Z Gesundh Wiss. 2023;31(1):9-19. (PMID: 33489718)
Eur J Health Econ. 2020 Sep;21(7):977-982. (PMID: 32591957)
Hum Vaccin Immunother. 2013 Aug;9(8):1779-81. (PMID: 23896582)
Lancet Reg Health Eur. 2021 Feb;1:100012. (PMID: 33954296)
Mayo Clin Proc. 2015 Nov;90(11):1562-8. (PMID: 26541249)
Eur J Epidemiol. 2020 Aug;35(8):775-779. (PMID: 32785815)
Hum Vaccin Immunother. 2021 Jun 3;17(6):1612-1621. (PMID: 33242386)
Vaccine. 2020 Sep 29;38(42):6500-6507. (PMID: 32863069)
Hum Vaccin Immunother. 2020 Sep 1;16(9):2204-2214. (PMID: 32730103)
Nat Med. 2021 Feb;27(2):225-228. (PMID: 33082575)
J Infect Dev Ctries. 2020 Oct 31;14(10):1098-1105. (PMID: 33175702)
Front Public Health. 2020 Jul 14;8:381. (PMID: 32760691)
Vaccines (Basel). 2021 Jan 18;9(1):. (PMID: 33477725)
Vaccines (Basel). 2020 Aug 27;8(3):. (PMID: 32867224)
J Community Health. 2021 Apr;46(2):270-277. (PMID: 33389421)
J Public Health (Oxf). 2021 Apr 12;43(1):13-25. (PMID: 33057666)
Epidemiologia (Basel). 2020 Dec 22;2(1):1-13. (PMID: 36417185)
JAMA. 2020 Dec 29;:. (PMID: 33372943)
Vaccine. 2016 Jun 8;34(27):3119-3124. (PMID: 27156636)
J Ambul Care Manage. 2021 Jan/Mar;44(1):71-75. (PMID: 33165121)
Lancet. 2020 Sep 26;396(10255):898-908. (PMID: 32919524)
Nat Commun. 2021 Jan 4;12(1):29. (PMID: 33397962)
Vaccines (Basel). 2020 Sep 25;8(4):. (PMID: 32992864)
Med Lav. 2020 Nov 17;111(6):445-448. (PMID: 33311419)
Can Commun Dis Rep. 2020 May 07;46(5):155-159. (PMID: 32558811)
J Public Health Res. 2020 Oct 14;9(4):1794. (PMID: 33117758)
Nat Med. 2021 Feb;27(2):205-211. (PMID: 33469205)
BMJ Open. 2017 Sep 7;7(9):e017142. (PMID: 28882921)
Lancet Infect Dis. 2021 May;21(5):e110. (PMID: 32941786)
Cad Saude Publica. 2014 Jan;30(1):21-9. (PMID: 24627010)

0 (COVID-19 Vaccines)

Date Created: 20210427 Date Completed: 20210507 Latest Revision: 20240401

20240401

PMC8078802

10.1371/journal.pone.0250495

33905442